裸盖菇素:从精神科弃儿到被视作万能药
作者系统检索1998年1月至2023年11月PubMed关于裸盖菇素联合心理支持/治疗(PST)的文献,纳入21项开放标签或随机对照试验,覆盖强迫症及相关障碍、癌症相关焦虑/抑郁、重性抑郁障碍(MDD)、物质使用障碍、厌食症及艾滋病幸存者丧失士气。证据最充分的是MDD(三项双盲随机对照试验显示积极信号),但存在盲法失败、样本小、给药与PST方案差异大、样本多样性有限及可能的期望效应等内部与外部效度威胁。结论认为证据尚不足以推荐裸盖菇素联合PST作为精神科治疗,需更严谨的临床试验。
要点
- 共纳入21项开放标签或随机对照试验,覆盖强迫症及相关障碍、癌症相关焦虑/抑郁、MDD、物质使用障碍、厌食症及艾滋病幸存者丧失士气。
- MDD证据最充分,有三项双盲随机对照试验显示积极信号,跨越一系列严重程度。
- 证据受盲法失败、样本小、给药与PST方案变异大、样本多样性有限及可能的大期望效应限制。
核心结论
- 证据目前不足以推荐裸盖菇素联合PST作为精神科治疗。
- 需要更严谨设计的临床试验在更大且更多样的样本中明确疗效、处理给药考虑、改进盲法并提供作用机制与临床应答调节因素的信息。
- 与其他循证治疗的头对头比较将更好地为裸盖菇素联合PST未来在重性精神障碍治疗中的潜在角色提供信息。
研究设计与样本
- 检索PubMed 1998年1月至2023年11月的英文文献,检索词为「psilocybin」,共识别1449篇文章并经标题和摘要筛选。
- 纳入21项独特的开放标签或随机对照试验(RCT),考察裸盖菇素治疗强迫症及相关障碍(N=2)、癌症诊断相关焦虑/抑郁(N=5)、重性抑郁障碍(MDD;N=8)、物质使用障碍(N=4)、厌食症(N=1)及艾滋病幸存者丧失士气(即绝望、无助和应对不良;N=1)。
主要发现
- 证据基础最成熟的是MDD治疗,有三项双盲RCT显示积极信号,跨越一系列严重程度。
- 证据受内部与外部效度威胁的影响,包括盲法失败、样本小、给药与PST程序变异大、样本多样性有限以及可能的大期望效应。
- 目前对作用机制和应答预测因素的知识有限。
临床怎么用
- 原文未据此给出推荐。
- 作者认为证据目前不足以推荐裸盖菇素联合PST作为精神科治疗。
局限性
- 证据受内部与外部效度威胁的影响,包括盲法失败。
- 证据受样本小的限制。
- 证据受给药与PST程序变异大的限制。
- 证据受样本多样性有限的限制。
- 证据受可能的大期望效应的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors. METHODS: PubMed was searched for English-language articles from January 1998 to November 2023, using the search term "psilocybin." A total of 1,449 articles were identified and screened through titles and abstracts. Of these, 21 unique open-label or randomized controlled trials (RCTs) were identified that examine psilocybin for the treatment of obsessive-compulsive and related disorders (N=2), anxiety/depression associated with a cancer diagnosis (N=5), major depressive disorder (MDD; N=8), substance use disorders (N=4), anorexia (N=1), and demoralization (i.e., hopelessness, helplessness, and poor coping) in AIDS survivors (N=1). RESULTS: The most developed evidence base is for the treatment of MDD (three double-blind RCTs with positive signals spanning a range of severities). However, the evidence is tempered by threats to internal and external validity, including unsuccessful blinding, small samples, large variability in dosing and PST procedures, limited sample diversity, and possibly large expectancy effects. Knowledge of mechanisms of action and predictors of response is currently limited. CONCLUSIONS: The evidence is currently insufficient to recommend psilocybin with PST as a psychiatric treatment. Additional rigorously designed clinical trials are needed to definitively establish efficacy in larger and more diverse samples, address dosing considerations, improve blinding, and provide information on mechanisms of action and moderators of clinical response. Head-to-head comparisons with other evidence-based treatments will better inform the potential future role of psilocybin with PST in the treatment of major psychiatric disorders.
引用
- Fonzo GA, Wolfgang AS, Barksdale BR, et al. Psilocybin: From Psychiatric Pariah to Perceived Panacea. Am J Psychiatry. 2025. PMID: 39741437. doi:10.1176/appi.ajp.20230682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。